1 study on NRP1-PDC curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study highlights the significant potential of NRP1-PDC as a dual-action therapeutic strategy for highly aggressive cancers like glioblastoma. By simultaneously targeting tumor cells and their blood supply through…
Free, no account — handy when you're working with NRP1-PDC.